An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine.

References

• Treede RD, Rief W, Barke A, et al. Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the International Classification of Diseases (ICD-11). Pain. 2019;160(1):19–27. doi:10.1097/j.pain.0000000000001384
   PubMed Web of Science ®Google Scholar
• Mills SEE, Nicolson KP, Smith BH. Chronic pain: a review of its epidemiology and associated factors in population-based studies. Br J Anaesth. 2019;123(2):e273–e283. doi:10.1016/j.bja.2019.03.023
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr, Raffa RB. Safety and efficacy of the unique opioid buprenorphine for the treatment of chronic pain. J Pain Res. 2019;13(12):3299–3317. doi:10.2147/JPR.S231948
   Web of Science ®Google Scholar
• Hylands-White N, Duarte RV, Raphael JH. An overview of treatment approaches for chronic pain management. Rheumatol Int. 2017;37(1):29–42. doi:10.1007/s00296-016-3481-8
   PubMed Web of Science ®Google Scholar
• Fornasari D, Gerra G, Maione S, et al. Treatment of chronic pain in Italy: therapeutic appropriacy of opioids and fear of addiction: the situation in Italy vs. USA. Pharmaadvances. 2020;1:31–40.
   Google Scholar
• Pergolizzi JV Jr, Scholten W, Smith KJ, Leighton-Scott J, Willis JC, Henningfield JE. The unique role of transdermal buprenorphine in the global chronic pain epidemic. Acta Anaesthesiol Taiwan. 2015;53(2):71–76. doi:10.1016/j.aat.2015.06.001
   PubMedGoogle Scholar
• van Hecke O, Torrance N, Smith BH. Chronic pain epidemiology and its clinical relevance. Br J Anaesth. 2013;111(1):13–18. doi:10.1093/bja/aet123
   PubMed Web of Science ®Google Scholar
• Guillou-Landreat M, Quinio B, Le Reste JY, et al. Analgesic opioid misuse and opioid use disorder among patients with chronic non-cancer pain and prescribed opioids in a pain centre in France. Int J Environ Res Public Health. 2021;18(4):2097. doi:10.3390/ijerph18042097
   PubMed Web of Science ®Google Scholar
• Higgins C, Smith BH, Matthews K. Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta-analysis. Br J Anaesth. 2018;120(6):1335–1344. doi:10.1016/j.bja.2018.03.009
   PubMed Web of Science ®Google Scholar
• Davis MP, Mehta Z. Opioids and chronic pain: where is the balance? Curr Oncol Rep. 2016;18(12):71. PMID: 27812860. doi:10.1007/s11912-016-0558-1.
   Web of Science ®Google Scholar
• Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage. 2005;29(3):297–326.
   PubMed Web of Science ®Google Scholar
• Webster LR, Hansen E, Cater J, Smith T. A Phase I placebo-controlled trial comparing the effects of buprenorphine buccal film and oral oxycodone hydrochloride administration on respiratory drive. Adv Ther. 2020;37(11):4685–4696. doi:10.1007/s12325-020-01481-0
   Web of Science ®Google Scholar
• Pedersen MF, Wróbel TM, Märcher-Rørsted E, et al. Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics. Neuropharmacology. 2020;166:107718. doi:10.1016/j.neuropharm.2019.107718
   PubMed Web of Science ®Google Scholar
• Behzadi M, Joukar S, Beik A. Opioids and cardiac arrhythmia: a literature review. Med Princ Pract. 2018;27(5):401–414. doi:10.1159/000492616
   PubMed Web of Science ®Google Scholar
• Harris SC, Morganroth J, Ripa SR, Thorn MD, Colucci S. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive and placebo-controlled trials. Postgrad Med. 2017;129(1):69–80. doi:10.1080/00325481.2017.1270156
   PubMed Web of Science ®Google Scholar
• Fishman MA, Kim PS. Buprenorphine for chronic pain: a systemic review. Curr Pain Headache Rep. 2018;22(12):83. doi:10.1007/s11916-018-0732-2
   PubMed Web of Science ®Google Scholar
• Mills S, Torrance N, Smith BH. Identification and management of chronic pain in primary care: a review. Curr Psychiatry Rep. 2016;18(2):22. doi:10.1007/s11920-015-0659-9
   PubMed Web of Science ®Google Scholar
• Jones J, Hunter D. Consensus methods for medical and health services research. BMJ. 1995;311:376–380. doi:10.1136/bmj.311.7001.376
   PubMed Web of Science ®Google Scholar
• Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochem Pharmacol. 2020;180:114147. doi:10.1016/j.bcp.2020.114147
   PubMed Web of Science ®Google Scholar
• Ingrasciotta Y, Sultana J, Giorgianni F, et al. Analgesic drug use in elderly persons: a population-based study in Southern Italy. PLoS One. 2019;14(9):e0222836. doi:10.1371/journal.pone.0222836
   Web of Science ®Google Scholar
• Anekar AA, Cascella M. WHO analgesic ladder. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; May 17, 2020. PMID: 32119322.
   Google Scholar
• Yang J, Bauer BA, Wahner-Roedler DL, Chon TY, Xiao L. The modified WHO analgesic ladder: is it appropriate for chronic non-cancer pain? J Pain Res. 2020;17(13):411–417. doi:10.2147/JPR.S244173
   Web of Science ®Google Scholar
• Lippe PM, Brock C, David J, Crossno R, Gitlow S. The first national pain medicine summit–final summary report. Pain Med. 2010;11(10):1447–1468. doi:10.1111/j.1526-4637.2010.00961.x
   PubMed Web of Science ®Google Scholar
• Cuomo A, Bimonte S, Forte CA, Botti G, Cascella M. Multimodal approaches and tailored therapies for pain management: the trolley analgesic model. J Pain Res. 2019;12:711–714. doi:10.2147/JPR.S178910
   PubMed Web of Science ®Google Scholar
• Staunton CA, Lewis R, Barrett-Jolley R. Ion channels and osteoarthritic pain: potential for novel analgesics. Curr Pain Headache Rep. 2013;17(12):378. doi:10.1007/s11916-013-0378-z
   Web of Science ®Google Scholar
• Malfait AM, Schnitzer TJ. Towards a mechanism-based approach to pain management in osteoarthritis. Nat Rev Rheumatol. 2013;9(11):654–664. doi:10.1038/nrrheum.2013.138
   PubMed Web of Science ®Google Scholar
• Fu K, Robbins SR, McDougall JJ. Osteoarthritis: the genesis of pain. Rheumatology. 2018;57(suppl_4):iv43–iv50. doi:10.1093/rheumatology/kex419
   PubMed Web of Science ®Google Scholar
• Chen L, Vo T, Seefeld L, et al. Lack of correlation between opioid dose adjustment and pain score change in a group of chronic pain patients. J Pain. 2013;14(4):384–392. doi:10.1016/j.jpain.2012.12.012
   PubMed Web of Science ®Google Scholar
• Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58–68. doi:10.1016/S1470-2045(12)70040-2
   PubMed Web of Science ®Google Scholar
• Varrassi G, De Conno F, Orsi L, et al. Cancer pain management: an Italian Delphi survey from the Rational Use of Analgesics (RUA) group. J Pain Res. 2020;8(13):979–986. doi:10.2147/JPR.S243222
   Web of Science ®Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain – United States, 2016. JAMA. 2016;315:1624–1634. doi:10.1001/jama.2016.1464
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Kaye AM, Knezevic NN, et al. Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician. 2017;20(2S):S3–S92. doi:10.36076/ppj.2017.s92
   PubMed Web of Science ®Google Scholar
• Pedersen L, Borchgrevink PC, Riphagen II, Fredheim OM. Long- or short-acting opioids for chronic non-malignant pain? A qualitative systematic review. Acta Anaesthesiol Scand. 2014;58(4):390–401. doi:10.1111/aas.12279
   Web of Science ®Google Scholar
• Glanz JM, Binswanger IA, Shetterly SM, Narwaney KJ, Xu S. Association between opioid dose variability and opioid overdose among adults prescribed long-term opioid therapy. JAMA Netw Open. 2019;2(4):e192613. doi:10.1001/jamanetworkopen.2019.2613
   PubMed Web of Science ®Google Scholar
• Davis MP, Pasternak G, Behm B. Treating chronic pain: an overview of clinical studies centered on the buprenorphine option. Drugs. 2018;78(12):1211–1228. doi:10.1007/s40265-018-0953-z
   PubMed Web of Science ®Google Scholar
• Ding Z, Raffa RB. Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. Br J Pharmacol. 2009;157(5):831–843. doi:10.1111/j.1476-5381.2009.00209.x
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Billeci D, Maggi M, Corona G. Testosterone deficiency in non-cancer opioid-treated patients. J Endocrinol Investig. 2018;41:1377–1388. doi:10.1007/s40618-018-0964-3
   PubMed Web of Science ®Google Scholar
• Bawor M, Bami H, Dennis BB, et al. Testosterone suppression in opioid users: a systematic review and meta-analysis. Drug Alcohol Depend. 2015;1(149):1–9. doi:10.1016/j.drugalcdep.2015.01.038
   Web of Science ®Google Scholar
• Lamprecht A, Sorbello J, Jang C, Torpy DJ, Inder WJ. Secondary adrenal insufficiency and pituitary dysfunction in oral/trans- dermal opioid users with non-cancer pain. Eur J Endocrinol. 2018;179:353–362. doi:10.1530/EJE-18-0530
   Web of Science ®Google Scholar
• Aloisi AM, Aurilio C, Bachiocco V, et al. Endocrine consequences of opioid therapy. Psychoneuroendocrino. 2009;34(Suppl 1):S162–S168. doi:10.1016/j.psyneuen.2009.05.013
   Google Scholar
• Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D, Klingmuller D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2005;90:203–206. doi:10.1210/jc.2004-0929
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr, Coluzzi F, Taylor R Jr. Transdermal buprenorphine for moderate chronic noncancer pain syndromes. Expert Rev Neurother. 2018;18(5):359–369. doi:10.1080/14737175.2018.1462701
   PubMed Web of Science ®Google Scholar
• Pacifico S, Ferrari F, Albanese V, et al. Biased agonism at nociceptin/orphanin FQ receptors: a structure activity study on N/OFQ (1-13)-NH2. J Med Chem. 2020;63(19):10782–10795. doi:10.1021/acs.jmedchem.9b02057
   Web of Science ®Google Scholar
• Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature. 2000;408(6813):720–723. doi:10.1038/35047086
   PubMed Web of Science ®Google Scholar
• Austin Zamarripa C, Edwards SR, Qureshi HN, Yi JN, Blough BE, Freeman KB. The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats. Drug Alcohol Depend. 2018;192:158–162. doi:10.1016/j.drugalcdep.2018.08.002
   PubMed Web of Science ®Google Scholar
• Stein M, Herman D, Conti M, Anderson B, Bailey G. Initiating buprenorphine treatment for opioid use disorder during short-term in-patient ‘detoxification’: a randomized clinical trial. Addiction. 2020;115(1):82–94. doi:10.1111/add.14737
   PubMed Web of Science ®Google Scholar
• Likar R. Transdermal buprenorphine in the management of persistent pain - safety aspects. Ther Clin Risk Manag. 2006;2(1):115–125.
   PubMedGoogle Scholar
• Simpson RW, Wlodarczyk JH. Transdermal buprenorphine relieves neuropathic pain: a randomized, double-blind, parallel-group, placebo-controlled trial in diabetic peripheral neuropathic pain. Diabetes Care. 2016;39(9):1493–1500. doi:10.2337/dc16-0123
   PubMed Web of Science ®Google Scholar
• Coull JA, Beggs S, Boudreau D, et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature. 2005;438(7070):1017–1021. doi:10.1038/nature04223
   PubMed Web of Science ®Google Scholar
• Jacobsen JH, Watkins LR, Hutchinson MR. Discovery of a novel site of opioid action at the innate immune pattern-recognition receptor TLR4 and its role in addiction. Int Rev Neurobiol. 2014;118:129–163.
   Web of Science ®Google Scholar
• Hutchinson MR, Shavit Y, Grace PM, Rice KC, Maier SF, Watkins LR. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev. 2011;63(3):772–810. doi:10.1124/pr.110.004135
   PubMed Web of Science ®Google Scholar
• Demartini L, Terranova G, Innamorato MA, et al. Comparison of tonic vs burst spinal cord stimulation during trial period. Neuromodulation. 2019;22(3):327–332. doi:10.1111/ner.12867
   PubMed Web of Science ®Google Scholar
• Isagulyan E, Slavin K, Konovalov N, et al. Spinal cord stimulation in chronic pain: technical advances. Korean J Pain. 2020;33(2):99–107. PMID: 32235010; PMCID: PMC7136296. doi:10.3344/kjp.2020.33.2.99.
   Web of Science ®Google Scholar
• Heijmans L, Joosten EA. Mechanisms and mode of action of spinal cord stimulation in chronic neuropathic pain. Postgrad Med. 2020;132(sup3):17–21. PMID: 32403963. doi:10.1080/00325481.2020.1769393
   PubMed Web of Science ®Google Scholar
• Özcan Ç, Polat Ö, Çelik H, Uçar BY. The effect of paravertebral ozone injection in the treatment of low back pain. Pain Pract. 2019;19(8):821–825. doi:10.1111/papr.12812.
   Web of Science ®Google Scholar
• Costa T, Linhares D, Ribeiro da Silva M, Neves N. Ozone therapy for low back pain. A systematic review. Acta Reumatol Port. 2018;43(3):172–181.
   Web of Science ®Google Scholar
• Infantino R, Mattia C, Locarini P, Pastore AL, Maione S, Luongo L. Buprenorphine: far beyond the “ceiling”. Biomolecules. 2021;11(6):816. doi:10.3390/biom11060816
   Web of Science ®Google Scholar